Accessibility Menu
eFFECTOR Therapeutics logo

eFFECTOR Therapeutics(OTC) EFTR

Market Cap$3.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year+300%
1 Month+60%
$0.00
+300.00%
+0.00Today
eFFECTOR Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-20
eFFECTOR Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+300%USD 0.002026-08-13
1 month+60%USD 0.002026-07-21
3 month+60%USD 0.002026-05-22
Year to date+300%USD 0.002025-12-31
1 year+300%USD 0.002025-08-20
3 year-100%USD 17.502023-08-21
5 year-100%USD 245.002021-08-20
Since inception-100%USD 248.752021-03-01

eFFECTOR Therapeutics Financials at a Glance

Market Cap

$3.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$162.00K

Net Income (TTM)

-$34.63M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-14.87 (Low)

Price

$0.00

Volume

1,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.02

Estimated Earnings Date

Aug 20, 2026

EFTR News

elderly cancer patient

Why eFFECTOR Therapeutics Stock Is Heating Up Today

George Budwell, PhDSep 9, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative selective translation regulator inhibitors for cancer treatment. The company is advancing its lead investigational drug, Tomivosertib, and another compound, Zotatifin, both of which are currently in clinical trials.

Products and Services
  • Tomivosertib: An oral small molecule targeting MNK for metastatic non-small cell lung cancer
  • Zotatifin: A small-molecule therapeutic designed to inhibit eIF4E for various solid tumors
  • Strategic alliance with Pfizer Inc. for developing additional eIF4E inhibitors
Growth Outlook
  • Tomivosertib is in Phase 2b trials, indicating progress in clinical development
  • Zotatifin is also in Phase 2 trials, expanding the therapeutic pipeline
  • Partnership with Pfizer enhances research capabilities and market reach
Financial Highlights
  • Recent quarterly revenue of $0, reflecting ongoing clinical development phase
  • Cash and short-term investments totaled $25.4 million as of March 31, 2024
  • Net income for Q1 2024 was a loss of $8.8 million, consistent with R&D investments
eFFECTOR Therapeutics, Inc. operates in the biotechnology sector, focusing on innovative cancer therapies. The company is currently in the clinical development stage, with its primary investigational drug, Tomivosertib, undergoing a Phase 2b clinical study. This drug targets MNK, a key regulator in cancer cell growth, and aims to provide a new treatment option for patients with metastatic non-small cell lung cancer. Additionally, Zotatifin, another promising compound, is in Phase 2 trials, targeting eIF4E to treat various solid tumors. The growth outlook for eFFECTOR is bolstered by its ongoing clinical trials and strategic partnership with Pfizer, which enhances its research capabilities. The company’s financial position, with significant cash reserves, supports its continued investment in research and development, despite reporting no revenue in recent quarters. The focus remains on advancing its drug candidates through clinical trials, which could lead to potential market opportunities in the future.
AI Generated • Aug 10, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Stephen T. Worland, PhD

Website

www.effector.com

Headquarters

Solana Beach, CA 92075, US

EFTR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3771.56%

Return on Capital

-229.45%

Return on Assets

-174.31%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.70M

Volume

1.00K

Avg. Volume

1.54K

Financials (TTM)

Gross Profit

$51.00K

Operating Income

-$33.15M

EBITDA

-$31.84M

Operating Cash Flow

-$29.19M

Capital Expenditure

-$84.00K

Free Cash Flow

-$29.28M

Cash & ST Invst.

$25.38M

Total Debt

$20.25M

eFFECTOR Therapeutics Performance Analysis

eFFECTOR Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 3,553,000N/A
20232023-12-31USD 0N/A
eFFECTOR Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30N/A
Q32023-09-30N/A
Q42023-12-31N/A
Q12024-03-31-100.0%
eFFECTOR Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD 9.78N/A
20222022-12-31USD -13.76N/A
20232023-12-31USD -16.3719.0%
eFFECTOR Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3026.7%
Q32023-09-3023.1%
Q42023-12-31-1.8%
Q12024-03-313.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$28.00K

+0.0%

Gross Margin

0.00%

N/A

Market Cap

$3.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$271.43

N/A

Employees

14

N/A

Net Income

-$8.83M

+11.8%

EBITDA

-$8.06M

+13.3%

Quarterly Fundamentals

Name
Q1 2024YOY CHG

Total Cash

$25.38M

+33.5%

Total Debt

$20.25M

-0.5%

Accounts Receivable

$17.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$179.00K

+316.3%

Short Term Debt

$20.07M

-1.2%

Return on Assets

-1.74%

N/A

Return on Invested Capital

6.44%

N/A

Free Cash Flow

-$7.28M

+4.9%

Operating Cash Flow

-$7.28M

+4.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OMMHOmnimmune Holdings, Inc.
$0.00-0.00%
UTRSMinerva Surgical, Inc.
$0.00+0.00%
PROTProteonomix, Inc.
$0.00+25.00%
ATRXAdhera Therapeutics Inc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About EFTR

What is the current price of eFFECTOR Therapeutics?

eFFECTOR Therapeutics is trading at $0.00 per share.

What is the 52-week range for eFFECTOR Therapeutics?

Over the past 52 weeks, eFFECTOR Therapeutics has traded between $0.00 and $0.02.

How much debt does eFFECTOR Therapeutics have?

As of the most recent reporting period, eFFECTOR Therapeutics reported total debt of $19.45M.

How much cash does eFFECTOR Therapeutics have on hand?

eFFECTOR Therapeutics reported $14.88M in cash and cash equivalents in its most recent financial results.

What is eFFECTOR Therapeutics’s dividend yield?

eFFECTOR Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services